Joseph Schwartz
Stock Analyst at Leerink Partners
(3.19)
# 1,038
Out of 4,829 analysts
139
Total ratings
31.78%
Success rate
17.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Downgrades: Market Perform | $7 | $7.87 | -11.05% | 3 | Apr 30, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $9.62 | +191.06% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $20.02 | +99.80% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.40 | +3,402.63% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $5.36 | -25.37% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.20 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $2.76 | +334.78% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.41 | +231.95% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.12 | -10.71% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $3.50 | +71.43% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $44.23 | +8.52% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $16.60 | +8.43% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $11.90 | +68.14% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $32.30 | +5.28% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $58.86 | +120.86% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $36.27 | +341.14% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $151.46 | +7.62% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.11 | +800.90% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.50 | +2,107.36% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.00 | +50.00% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $35.11 | +207.60% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $65.08 | -23.17% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $30.68 | +27.12% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.61 | +148.45% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $14.58 | +105.76% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $27.87 | +79.40% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $42.95 | -30.15% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $12.79 | +337.84% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.99 | +133.92% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.61 | +647.66% | 2 | Sep 26, 2017 |
Regulus Therapeutics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $7
Current: $7.87
Upside: -11.05%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $9.62
Upside: +191.06%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $20.02
Upside: +99.80%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.40
Upside: +3,402.63%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $5.36
Upside: -25.37%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $2.76
Upside: +334.78%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.41
Upside: +231.95%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.12
Upside: -10.71%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.50
Upside: +71.43%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $44.23
Upside: +8.52%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $16.60
Upside: +8.43%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.90
Upside: +68.14%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $32.30
Upside: +5.28%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $58.86
Upside: +120.86%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $36.27
Upside: +341.14%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $151.46
Upside: +7.62%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.11
Upside: +800.90%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.50
Upside: +2,107.36%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.00
Upside: +50.00%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $35.11
Upside: +207.60%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $65.08
Upside: -23.17%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $30.68
Upside: +27.12%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.61
Upside: +148.45%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $14.58
Upside: +105.76%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $27.87
Upside: +79.40%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $42.95
Upside: -30.15%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $12.79
Upside: +337.84%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $5.99
Upside: +133.92%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.61
Upside: +647.66%